Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

Bristol Myers Squibb Co BMY announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).
Data were presented at the European Society for Medical Oncology Virtual Congress 2021 (ESMO21).
Related Link: Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting.
The Phase 3 CheckMate-214 trial showed a five-year survival rate of 48% and 37% for those receiving sunitinib.
After a median follow-up of 67.7 months, patients on the dual immunotherapy lived a median of 47 months versus 26.6 months for Pfizer Inc's PFE targeted therapy Sutent (sunitinib).
Opdivo plus Yervoy continued to show a higher ORR (39% vs. 32%) and complete response rate than sunitinib (12% vs. 3%).
Also, more patients treated with the combination achieved complete responses and subsequently did not progress (9.6% vs. 2.4%).
The safety profile of Opdivo plus Yervoy was manageable.
Related: Bristol Myers Scores FDA Approval For Opdivo In Postsurgery Bladder Cancer.
Price Action: BMY stock is down 1.66% at $60.97 during the market session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)